People in the News
Australian molecular diagnostics firm Genetic Signatures has appointed Stephane Chatonsky as a non-executive director. Chatonsky Chatonsky has held senior executive roles with global organizations including Lazard, McKinsey & Co, Macquarie Bank, and LeapFrog Investments. He has also held non-executive director, chair, and advisory positions for several pathology, healthcare, and technology companies.
Durin Technologies has appointed Mert Sahin as CEO.
Sahin previously led marketing for GE Healthcare's imaging business in the US and Canada and has also held roles at Roche Diagnostics, Eurofins Genomics, Thermo Fisher Scientific and Dalan Animal Health.
Octave Biosciences has named Doug Biehn president and CEO. Former CEO William Hagstrom is now chairman of the company's board of directors.
Biehn previously held executive positions at companies including iRhythm Technologies, McKesson, AliveCor, Blue Shield of California, and Cala Health.
BioAffinity Technologies has appointed Jamie Platt to its board of directors, effective Dec. 1. Currently, she is CEO and Managing Director of New Zealand-based IVD firm Pictor, as well as president and CEO of BridGenomics, a consulting and contracting commercialization company providing molecular and genomics-based advice. Prior to that, Platt was COO of Personal Genomice Diagnostics, now part of Laboratory Corporation of America, as well as COO of Inivata, which was acquired by NeoGenomics. She began her career at Quest Diagnostics where she became VP of genomic solutions at Molecular Pathology Laboratory Network.
Lucid Diagnostics has promoted Shaun O'Neil to the position of president. He also will remain as Lucid Dx's COO. He previously was the company's executive VP, and before that was its VP, and he has been its COO since the firm's founding.
Lucid Dx also appointed Natalie Carfora VP, market access, and James Fricchione VP, employer markets. Carfora previously had market access and commercial roles at Myriad Genetics and Eli Lilly. Fricchione was most recently SVP, sales and account management at Cobalt Benefit Group, a Blue Cross-owned third-party administrator.
Invitae appointed Ana Schrank as chief accounting officer, in addition to her current role as CFO, effective Nov. 21. Invitae stated that no new financial compensation accompanies Schrank's new role.
The British In Vitro Diagnostics Association has appointed Angela Douglas its president, effective Dec. 1. She was most recently deputy chief scientific officer for NHS England and previously was scientific director of the Cheshire and Merseyside Genetics and Genomics Service at Liverpool Women's Hospital, where she was also clinical program director. In 2012, Douglas was president of the British Society for Genetic Medicine. BIVDA represents in vitro diagnostic developers and manufacturers in the UK.
VedaBio, a San Diego-based developer of multiplexed CRISPR-based molecular detection technology, has formed its scientific advisory board comprising Rashid Bashir, Daniel Durocher, Patrick Hsu, and David Perlin.
Bashir is a company cofounder and was recently elected to the National Academy of Medicine. He has held numerous roles at the University of Illinois at Urbana-Champaign, currently serving as the dean of the Grainger College of Engineering and Grainger distinguished chair in bioengineering.
Durocher is chair of VedaBio's SAB and currently serves as senior investigator at the Lunenfeld-Tanenbaum Research Institute, cofounder and SAB member of Repare Therapeutics, and cofounder of Induxion Therapeutics. He is also a full professor at the University of Toronto.
Hsu is cofounder of the Arc Institute and assistant professor of bioengineering and a faculty fellow at the University of California, Berkeley. Previously, he served as principal investigator at the Salk Institute for Biological Studies.
Perlin currently serves as CSO and executive VP at Hackensack Meridian Health Center for Discovery and Innovation.
VedaBio launched last month with $40 million in Series A financing.
Don Hardison has been appointed as chairman of the board of Geneoscopy, a St. Louis-based developer of molecular diagnostic tests for gastrointestinal health. Hardison previously served as a strategic advisor to the company. He also previously served as president and CEO of Biotheranostics until its acquisition by Hologic in February 2021. Before that, he was president, CEO, and director at Good Start Genetics. Hardison was also president and CEO of Exact Sciences from 2000 to 2007, and has held multiple senior leadership positions at Labcorp, Quest Diagnostics, and SmithKline Beecham.